Latest news:

BioStock article: Follicum reaches milestone in hair study

BioStock published an article on 19 August 2020 about Follicum, which can be read in full below. Yesterday, Follicum announced that they have recruited over 50 per cent of the intended patient group for their ongoing phase IIa trial with the topical formulation of the hair growth stimulating candidate FOL-005. Thus, the study is well on […]

Sign up for our Newsletter

Follicum’s compliance with GDPR. Read more

Follicum's presentation at LSX World Congress 2020

Hair growth

Our drug candidate FOL-005 has demonstrated increased hair growth on both healthy individuals and on patients with alopecia in two clinical phase II trials, which both demonstrated good safety and efficacy.

Read more


Follicums pre-clinical research has resulted in a new peptide class which increased the release of insulin on mice

Read more


We want to develop safe, effective and cost effective drugs, suitable for both men and women, that have minimal side effects

Read more




17 Nov 20
BioStock Life Science Summit

Follicum will participate in the digital event BioStock Life Science Summit, which takes place 17-18...